Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab

被引：10

作者：

Korzenik, JR ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Dept Internal Med, Gastrointestinal Unit, Boston, MA 02114 USA

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2004年 / 33卷 / 02期

关键词：

D O I：

10.1016/j.gtc.2004.02.009

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The dramatic benefit experienced by many Crohn's patients treated with the anti-tumor necrosis factor-alpha (TNF-alpha) antibody infliximab underscores the centrality of this cytokine in the pathogenesis of Crohn's disease and the potential use of the therapeutic strategy of blocking TNF-alpha in this disease. In the hopes of emulating and improving on the success of infliximab, numerous strategies are being devised and studied to inhibit the actions of TNF-alpha. This article focuses on those agents, other than infliximab, which target TNF-alpha to treat inflammatory bowel disease as their central mechanism of action.

引用

页码：285 / +

页数：18

共 50 条

[21] Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor α antibody (infliximab) in Crohn's disease
Detková, Z
Kupcova, V
Príkazská, M
Turecky, L
Weissová, S
Jahnová, E
PHYSIOLOGICAL RESEARCH, 2003, 52 (01) : 95 - 100
[22] Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease
Kupcova, V
Turecky, L
Detková, Z
Príkazská, M
Keleová, A
PHYSIOLOGICAL RESEARCH, 2003, 52 (01) : 89 - 93
[23] Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease
Mir Subias, Alberto
Garcia-Lopez, Santiago
Sebastian Torres, Berta
Ollero Domenche, Leticia
Garcia Gamez, Andres
Gomollon, Fernando
GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (02): : 81 - 85
[24] Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-α Agents
Kestens, Christine
van Oijen, Martijn G. H.
Mulder, Charlotte L. J.
van Bodegraven, Ad A.
Dijkstra, Gerard
de Jong, Dirk
Ponsioen, Cyriel
van Tuyl, Bas A. C.
Siersema, Peter D.
Fidder, Herma H.
Oldenburg, Bas
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (07) : 826 - 831
[25] Infliximab-Associated Psoriasis in Children With Crohn's Disease May Require Withdrawal of Anti-Tumor Necrosis Factor Therapy
Broge, Tangra
Nam Nguyen
Sacks, Alan
Davis, Michael
INFLAMMATORY BOWEL DISEASES, 2013, 19 (05) : E75 - E77
[26] Functional modulation of crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies
Di Sabatino, Antonio
Pender, Sylvia L. F.
Jackson, Claire L.
Prothero, Joanna D.
Gordon, John N.
Picariello, Lucia
Rovedatti, Laura
Docena, Guillermo
Monteleone, Giovanni
Rampton, David S.
Tonelli, Francesco
Corazza, Gino R.
Macdonald, Thomas T.
GASTROENTEROLOGY, 2007, 133 (01) : 137 - 149
[27] Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
Osterman, Mark T.
Haynes, Kevin
Delzell, Elizabeth
Zhang, Jie
Bewtra, Meenakshi
Brensinger, Colleen M.
Chen, Lang
Xie, Fenglong
Curtis, Jeffrey R.
Lewis, James D.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : 1293 - +
[28] Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease
Nguyen, Douglas L.
Flores, Sarah
Sassi, Kareem
Bechtold, Matthew L.
Nguyen, Emily T.
Parekh, Nimisha K.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (03) : 147 - 154
[29] Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
Laurie S. Conklin
Bernard Cohen
Lindsay Wilson
Carmen Cuffari
Maria Oliva-Hemker
Nature Reviews Gastroenterology & Hepatology, 2010, 7 : 174 - 177
[30] Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease
Suenaert, P
Bulteel, V
Lemmens, L
Noman, M
Geypens, B
Van Assche, G
Geboes, K
Ceuppens, JL
Rutgeerts, P
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (08): : 2000 - 2004

← 1 2 3 4 5 →